English
教員紹介
閉じる
アオキ マナブ
青木 学
所属
保健科学部 医学検査学科
保健科学研究科 保健科学専攻
職種
教授
著書・論文等
著書
臨床開発のパイプラインにある新規化合物 医学のあゆみ 284 (9),719-725頁 (共著) 2023/03
論文
An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier PNAS Nexus (共著) 2025/01
論文
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants Science Advances (共著) 2023/07/12
論文
Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2 Nature Communications (共著) 2023
論文
Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands. ChemMedChem (共著) 2022
論文
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Scientific Reports (共著) 2020
論文
A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Global Health & Medicine 1,36--48頁 (共著) 2019
論文
Novel protease inhibitors containing C-5-modified bis-THF and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with high genetic barrier against the emergence of drug resistance. Antimicrobial Agents and Chemotherapy 25 (63(8)),e00372--19頁 (共著) 2019
論文
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. 6 (9(2)),e02425--17頁 (共著) 2018
論文
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. eLife 17 (6),e28020 (共著) 2017
論文
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Jornal of Virology 18 (90(5)),01829--15頁 (共著) 2015
閉じる